Lista de obras - Cara Haymaker - Dominio Público Uruguay

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

artículo científico publicado en 2016

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

artículo científico publicado en 2017

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

artículo científico publicado en 2019

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

artículo científico publicado en 2017

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2016

Absence of Grail promotes CD8+ T cell anti-tumour activity

artículo científico

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

artículo científico publicado en 2014

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

artículo científico publicado en 2012

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

artículo científico publicado en 2020

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

artículo científico publicado en 2015

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

scientific article published on 21 May 2020

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

artículo científico publicado en 2020

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity

artículo científico publicado en 2013

EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer

artículo científico publicado en 2023

Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies

artículo científico publicado en 2021

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

artículo científico publicado en 2017

Evolution of genomic and T cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment

scientific article published on 14 August 2020

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

artículo científico publicado en 2016

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

artículo científico publicado en 2017

Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells

artículo científico publicado en 2020

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy

artículo científico publicado en 2013

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

artículo científico publicado en 2015

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

artículo científico publicado en 2015

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

artículo científico publicado en 2017

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control

artículo científico publicado en 2015

Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter

artículo científico publicado en 2017

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

artículo científico publicado en 2021

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

artículo científico publicado en 2021

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

artículo científico publicado en 2016

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

artículo científico publicado en 2017

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

artículo científico publicado en 2015

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

artículo científico publicado en 2019

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer.

artículo científico publicado en 2015

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy

artículo científico publicado en 2014

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

RNA editing derived epitopes function as cancer antigens to elicit immune responses

scientific article published in Nature Communications

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

artículo científico publicado en 2016

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients.

artículo científico publicado en 2015

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.

artículo científico publicado en 2017

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression.

artículo científico publicado en 2018

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity

artículo científico publicado en 2015

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells

artículo científico publicado en 2013

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

artículo científico publicado en 2018

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes

artículo científico publicado en 2015

Lista de obras de Cara Haymaker

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016

4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Absence of Grail promotes CD8+ T cell anti-tumour activity

Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity

EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer

Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies

Erratum to: A case report of Grover's disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1.

Evolution of genomic and T cell repertoire heterogeneity of malignant pleural mesothelioma under dasatinib treatment

Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells

Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.

Modification of BTLA signaling motifs in TIL exhibits positive signals that mediate anti-tumor control

Multifaceted role of BTLA in the control of CD8+ T cell fate after antigen encounter

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Pilot study of intratumoral (IT) cryoablation (cryo) in combination with systemic checkpoint blockade in patients with metastatic melanoma (MM).

Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy

Preclinical development of tumor-infiltrating lymphocyte therapy for ovarian cancer.

Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

RNA editing derived epitopes function as cancer antigens to elicit immune responses

Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report

Single-cell motility and gene expression signature as predictors of the overall survival of act in melanoma patients.

The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.

The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression.

The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity

Uncovering a novel function of BTLA on tumor-infiltrating CD8+ T cells

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

You can run but you can't hide: tracking T cells in metastatic melanoma patients treated with tumor-infiltrating lymphocytes